Cargando…

HTA decision-making for drugs for rare diseases: comparison of processes across countries

INTRODUCTION: Drugs for rare diseases (DRDs) offer important health benefits, but challenge traditional health technology assessment, reimbursement, and pricing processes due to limited effectiveness evidence. Recently, modified processes to address these challenges while improving patient access ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stafinski, Tania, Glennie, Judith, Young, Andrea, Menon, Devidas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264608/ https://www.ncbi.nlm.nih.gov/pubmed/35804398 http://dx.doi.org/10.1186/s13023-022-02397-4

Ejemplares similares

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe
por: Stafinski, Tania, et al.
Publicado: (2011)

Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
por: Paulden, Mike, et al.
Publicado: (2014)

Decision-Making on New Non-Drug Health Technologies by Hospitals and Health Authorities in Canada
por: Stafinski, Tania, et al.
Publicado: (2019)

Moving beyond the Court of Public Opinion: A Citizens’ Jury Exploring the Public’s Values around Funding Decisions for Ultra-Orphan Drugs
por: Stafinski, Tania, et al.
Publicado: (2022)

HTA and National Immunisation Program: an overview of competent bodies and of the impact of HTA on the decision-making process
por: Ricciardi, W
Publicado: (2022)

Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada
por: Nagase, Fernanda Naomi Inagaki, et al.
Publicado: (2019)

Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle
por: Menon, Devidas, et al.
Publicado: (2015)

Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review
por: Young, Andrea, et al.
Publicado: (2017)

Capturing the Impact of Patient Portals Based on the Quadruple Aim and Benefits Evaluation Frameworks: Scoping Review
por: Avdagovska, Melita, et al.
Publicado: (2020)

Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations
por: Yuba, Tania Yuka, et al.
Publicado: (2018)

Tracing the Decisions That Shaped the Development of MyChart, an Electronic Patient Portal in Alberta, Canada: Historical Research Study
por: Avdagovska, Melita, et al.
Publicado: (2020)

Effectiveness of photodynamic therapy for mammary and extra-mammary Paget's disease: a state of the science review
por: Nardelli, Alexa A, et al.
Publicado: (2011)

The Medical Devices Special Access Program in Canada: A Scoping Study
por: Maier, Roland K., et al.
Publicado: (2018)

HTA Metro Map: a patient centred model for optimizing the decision making process
por: Chiumente, Marco, et al.
Publicado: (2019)

Correction: Predicting Survival after Liver Transplantation Based on Pre-Transplant MELD Score: a Systematic Review of the Literature
por: Klein, Kristin B., et al.
Publicado: (2013)

Barriers and facilitators to evidence-use in program management: a systematic review of the literature
por: Humphries, Serena, et al.
Publicado: (2014)

The Impact of Secure Messaging in the Treatment of Patients With Diabetes Within a Primary Care Setting: Protocol for a Scoping Review
por: Lawal, Abdul, et al.
Publicado: (2023)

A checklist for managed access programmes for reimbursement co‐designed by Canadian patients and caregivers
por: Young, Andrea, et al.
Publicado: (2018)

The Introduction of New Non-Drug Health Technologies into Canadian Healthcare Institutions: Opportunities and Challenges
por: Stafinski, Tania, et al.
Publicado: (2019)

Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy
por: Menon, Devidas, et al.
Publicado: (2010)

Assisted reproductive technologies (ARTs): Evaluation of evidence to support public policy development
por: Nardelli, Alexa A, et al.
Publicado: (2014)

Patient Portal Implementation and Uptake: Qualitative Comparative Case Study
por: Avdagovska, Melita, et al.
Publicado: (2020)

Effectiveness of home-based pulmonary rehabilitation programs for patients with chronic obstructive pulmonary disease (COPD): systematic review
por: Stafinski, Tania, et al.
Publicado: (2022)

Predicting Survival after Liver Transplantation Based on Pre-Transplant MELD Score: a Systematic Review of the Literature
por: Klein, Kristin B., et al.
Publicado: (2013)

“Our Home Is a Muddy Structure”: Perceptions of Housing and Health Risks Among Older Adults in Contrasting Neighborhoods in Ghana
por: Alaazi, Dominic A., et al.
Publicado: (2021)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)

Effectiveness of remote home monitoring for patients with Chronic Obstructive Pulmonary Disease (COPD): systematic review
por: Nagase, Fernanda Inagaki, et al.
Publicado: (2022)

HTA Implementation Roadmap in Central and Eastern European Countries
por: Kaló, Zoltán, et al.
Publicado: (2016)

Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland
por: Lebioda, Andrea, et al.
Publicado: (2014)

Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?
por: Adkins, Elizabeth M, et al.
Publicado: (2017)

Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making
por: Gordon, Jason, et al.
Publicado: (2021)

POSC254 The Impact of COVID-19 on European HTA Decisions
por: Watson, C, et al.
Publicado: (2022)

Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR
por: Richter, Trevor, et al.
Publicado: (2018)

Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view
por: Giuliani, Giovanni, et al.
Publicado: (2018)

Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
por: Culyer, Anthony J.
Publicado: (2019)

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline
por: Chavarina, Kinanti Khansa, et al.
Publicado: (2023)

Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective
por: Kisser, Agnes, et al.
Publicado: (2021)

GMS-HTA: Information out of the world of HTA - up-to-date, comprehensive and valid
por: Rüther, Alric
Publicado: (2005)

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree
por: Dintsios, C. M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1pft8rgirk46sq6bccfksio2bd